{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:39:15Z","timestamp":1787981955232,"version":"build-2784847793"},"reference-count":17,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"DFG (German Research Society)","award":["MU 4603\/1-1 | OT 534\/3-1"],"award-info":[{"award-number":["MU 4603\/1-1 | OT 534\/3-1"]}]},{"name":"University of T\u00fcbingen","award":["MU 4603\/1-1 | OT 534\/3-1"],"award-info":[{"award-number":["MU 4603\/1-1 | OT 534\/3-1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Introduction: Novel MRI-linear accelerator hybrids (MR-Linacs, MRL) promise an optimization of radiotherapy (RT) through daily MRI imaging with enhanced soft tissue contrast and plan adaptation on the anatomy of the day. These features might potentially improve salvage RT of prostate cancer (SRT), where the clinical target volume is confined by the mobile organs at risk (OAR) rectum and bladder. So far, no data exist about the feasibility of the MRL technology for SRT. In this study, we prospectively examined patients treated with SRT on a 1.5 T MRL and report on workflow, feasibility and acute toxicity. Patients and Methods: Sixteen patients were prospectively enrolled within the MRL-01 study (NCT: NCT04172753). All patients were staged and had an indication for SRT after radical prostatectomy according to national guidelines. RT consisted of 66 Gy in 33 fractions or 66.5\/70 Gy in 35 fractions in case of a defined high-risk region. On the 1.5 T MRL, daily plan adaption was performed using one of two workflows: adapt to shape (ATS, using contour adaptation and replanning) or adapt to position (ATP, rigid replanning onto the online anatomy with virtual couch shift). Duration of treatment steps, choice of workflow and treatment failure were recorded for each fraction of each patient. Patient-reported questionnaires about patient comfort were evaluated as well as extensive reporting of acute toxicity (patient reported and clinician scored). Results: A total of 524\/554 (94.6%) of fractions were successfully treated on the MRL. No patient-sided treatment failures occurred. In total, ATP was chosen in 45.7% and ATS in 54.3% of fractions. In eight cases, ATP was performed on top of the initial ATS workflow. Mean (range) duration of all fractions (on-table time until end of treatment) was 25.1 (17.6\u201344.8) minutes. Mean duration of the ATP workflow was 20.60 (17.6\u201325.2) minutes and of the ATS workflow 31.3 (28.2\u201334.1) minutes. Patient-reported treatment experience questionnaires revealed high rates of tolerability of the treatment procedure. Acute toxicity (RTOG, CTC as well as patient-reported CTC, IPSS and ICIQ) during RT and 3 months after was mild to moderate with a tendency of recovery to baseline levels at 3 months post RT. No G3+ toxicity was scored for any item. Conclusions: In this first report on SRT of prostate cancer patients on a 1.5 T MRL, we could demonstrate the feasibility of both available workflows. Daily MR-guided adaptive SRT of mean 25.1 min per fraction was well tolerated in this pretreated collective, and we report low rates of acute toxicity for this treatment. This study suggests that SRT on a 1.5 T MRL can be performed in clinical routine and it serves as a benchmark for future analyses.<\/jats:p>","DOI":"10.3390\/jcm11164651","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T02:42:53Z","timestamp":1660099373000},"page":"4651","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["First Experience and Prospective Evaluation on Feasibility and Acute Toxicity of Online Adaptive Radiotherapy of the Prostate Bed as Salvage Treatment in Patients with Biochemically Recurrent Prostate Cancer on a 1.5T MR-Linac"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0012-6589","authenticated-orcid":false,"given":"Daniel","family":"Wegener","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Eberhard Karls University, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Thome","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Eberhard Karls University, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8836-528X","authenticated-orcid":false,"given":"Frank","family":"Paulsen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Eberhard Karls University, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0242-9428","authenticated-orcid":false,"given":"Cihan","family":"Gani","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Eberhard Karls University, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Boldt","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Eberhard Karls University, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Butzer","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Eberhard Karls University, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1433-9315","authenticated-orcid":false,"given":"Daniela","family":"Thorwarth","sequence":"additional","affiliation":[{"name":"Section for Biomedical Physics, Department of Radiation Oncology, Eberhard Karls University, 72076 Tuebingen, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site T\u00fcbingen and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1828-9530","authenticated-orcid":false,"given":"David","family":"Moennich","sequence":"additional","affiliation":[{"name":"Section for Biomedical Physics, Department of Radiation Oncology, Eberhard Karls University, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8923-4740","authenticated-orcid":false,"given":"Marcel","family":"Nachbar","sequence":"additional","affiliation":[{"name":"Section for Biomedical Physics, Department of Radiation Oncology, Eberhard Karls University, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt-Christian","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Eberhard Karls University, 72076 Tuebingen, Germany"},{"name":"Department of Radiation Oncology, Klinikum Ludwigsburg, 71640 Ludwigsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Zips","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Eberhard Karls University, 72076 Tuebingen, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site T\u00fcbingen and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany"},{"name":"Department of Radiation Oncology, Charit\u00e9 Berlin, 10117 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3210-3368","authenticated-orcid":false,"given":"Simon","family":"Boeke","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Eberhard Karls University, 72076 Tuebingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"616156","DOI":"10.3389\/fonc.2021.616156","article-title":"Mr-guided radiotherapy for head and neck cancer: Current developments, perspectives, and challenges","volume":"11","author":"Boeke","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.radonc.2021.09.002","article-title":"A novel approach for radiotherapy dose escalation in rectal cancer using online mr-guidance and rectal ultrasound gel filling-rationale and first in human","volume":"164","author":"Gani","year":"2021","journal-title":"Radiother. Oncol."},{"key":"ref_3","first-page":"54","article-title":"Adaptive radiotherapy: The elekta unity mr-linac concept","volume":"18","author":"Winkel","year":"2019","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13014-020-01510-w","article-title":"1.5\u2009T mr-guided and daily adapted sbrt for prostate cancer: Feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment","volume":"15","author":"Alongi","year":"2020","journal-title":"Radiat. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"616291","DOI":"10.3389\/fonc.2020.616291","article-title":"Mr-guided radiotherapy for prostate cancer","volume":"10","author":"Tocco","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ijrobp.2020.11.010","article-title":"Prostate bed delineation guidelines for postoperative radiation therapy: On behalf of the francophone group of urological radiation therapy","volume":"109","author":"Robin","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"603994","DOI":"10.3389\/fonc.2020.603994","article-title":"The role of multiparametric magnetic resonance in volumetric modulated arc radiation therapy planning for prostate cancer recurrence after radical prostatectomy: A pilot study","volume":"10","author":"Sardaro","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate cancer, version 2.2019, nccn clinical practice guidelines in oncology","volume":"17","author":"Mohler","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_9","unstructured":"(2022, March 15). Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, Awmf): S3-Leitlinie Prostatakarzinom, Kurzversion 6.2, Oktober 2021, Awmf Registernummer: 043\/022ol. Available online: https:\/\/www.Leitlinienprogramm-onkologie.De\/leitlinien\/prostatakarzinom\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2018.01.014","article-title":"Estro acrop consensus guideline on ct- and mri-based target volume delineation for primary radiation therapy of localized prostate cancer","volume":"127","author":"Salembier","year":"2018","journal-title":"Radiother. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Almansour, H., Afat, S., Fritz, V., and Schick, F. (2021). Prospective image quality and lesion assessment in the setting of mr-guided radiation therapy of prostate cancer on an mr-linac at 1.5 t: A comparison to a standard 3 t mri. Cancers, 13.","DOI":"10.3390\/cancers13071533"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.phro.2021.05.002","article-title":"Automatic 3D Monte-Carlo-based secondary dose calculation for online verification of 1.5 T magnetic resonance imaging guided radiotherapy","volume":"19","author":"Nachbar","year":"2021","journal-title":"Phys. Imaging Radiat. Oncol."},{"key":"ref_13","first-page":"31","article-title":"Development and results of a patient-reported treatment experience questionnaire on a 1.5 t mr-linac","volume":"30","author":"Barnes","year":"2021","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.radonc.2020.06.044","article-title":"Prostate intrafraction motion during the preparation and delivery of mr-guided radiotherapy sessions on a 1.5t mr-linac","volume":"151","author":"Kerkmeijer","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (radicals-rt): A randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (getug-afu 17): A randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): A randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/16\/4651\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:06:10Z","timestamp":1760141170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/16\/4651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":17,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["jcm11164651"],"URL":"https:\/\/doi.org\/10.3390\/jcm11164651","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,9]]}}}